

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

28 November 2001 (28.11.01)

International application No.

PCT/IL01/00276

Applicant's or agent's file reference

135,220 PCT

International filing date (day/month/year)

22 March 2001 (22.03.01)

Priority date (day/month/year)

22 March 2000 (22.03.00)

Applicant

WOLNERMAN, Joseph, Simcha

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

16 October 2001 (16.10.01)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Odile ALIU

Telephone No.: (41-22) 338.83.38

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70184 A2

(51) International Patent Classification⁷: **A61K 7/26, 7/16**

(21) International Application Number: **PCT/IL01/00276**

(22) International Filing Date: **22 March 2001 (22.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
135,220 22 March 2000 (22.03.2000) IL

(71) Applicant (for all designated States except US): **GIN SOL LTD [IL/IL]; Hartum 9, Har Hotzvim, 91450 Jerusalem (IL).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WOLNERMAN, Joseph, Simcha [IL/IL]; Nelson Glick Street 32, 97233 Jerusalem (IL).**

(74) Agent: **WOLFF, BREGMAN AND GOLLER; P.O. Box 1352, 91013 Jerusalem (IL).**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/70184 A2

(54) Title: **A COMPOSITION CONTAINING MONOTERPENES FOR TOPICAL ORAL ADMINISTRATION**

(57) Abstract: The invention provides a composition for topical, oral administration for prevention and treatment of oral disease, comprising an active agent containing at least 70 % by weight monoterpenes with three unsaturations as active agent therein, in combination with a suitable carrier.

A COMPOSITION CONTAINING MONOTERPENES FOR TOPICAL
ORAL ADMINISTRATION

Field of the Invention:

The present invention relates to a composition for topical oral administration.

More specifically, the invention relates to a composition for topical oral administration comprising monoterpenes with three unsaturations including limonene and pinene from synthetic or essential oil natural extracts in combination with a suitable carrier.

Description of the Prior Art:

Dental calculus, or tartar, is recognized as a recurring calcified deposit on the surfaces of teeth. It is generally recognized that dental calculus develops in a sequential process that involves the accumulation of dental plaque and the subsequent calcification of the plaque by saliva, which has very high concentrations of calcium and phosphate. Although calculus, per se, is not directly responsible for the development of oral diseases, it is recognized as a secondary, or contributing, factor in the development of periodontal disease because: (1) its presence on the teeth serves as a local irritant to the adjacent soft tissues, eliciting an inflammatory response (and soft tissue inflammation is the initial phase of periodontal disease); (2) it interferes with the normal cleansing of the tooth surfaces, which occurs during the mastication of food or through the performance of conventional oral hygiene procedures, such as toothbrushing and flossing; and (3) it harbors bacterial toxins, which exacerbate periodontal disease formation, by virtue of its porosity. Once formed, calculus deposits can only be removed through concerted mechanical procedures, i.e., a dental prophylaxis, scaling or root planing in deep pockets..

Oral tissue diseases such as gingivitis and periodontitis are a common affliction which necessitate constant care for prevention and treatment. The domestic personal use of a toothbrush, toothpaste, mouthwash, dental floss and dental tooth picks are recommended for removing food particles, cleaning tooth surfaces and stimulating the gums.

While a toothbrush has a primary function of removing food particles, the toothpaste has secondary function. The toothpaste is provided to encourage brushing by its texture, flavor and odor.

The texture dampens the rigid-dry sensation of the toothbrush, while the flavoring and fragrant components mask the taste of therapeutic substances within the toothpaste. An example of such a substance is a detergent aimed at assisting the removal of fats which adhere to the teeth.

The prior art discloses compositions and methods that use oxidizing agents, antimicrobial agents, and antibiotics for the treatment of various oral care conditions. Most of these prior art references teach that the delivery of these agents is essential to provide efficacy. This is in contrast to the present invention which focuses on the delivery of natural agents, monoterpenes with three unsaturations, that unexpectedly show a strong activity to the oral cavity, to provide efficacy.

The prior art teaches a variety of ways to deliver oxidation agents, in oral care compositions, to the oral cavity. For example, U.S. Pat. Nos. 4,689,215 issued Aug. 25, 1987; 4,837,009 issued Jun. 6, 1989; 4,696,811, issued Sep. 29, 1987; 4,808,389 issued Feb. 28, 1989; 4,786,492 issued Nov. 22, 1988; 4,788,053 issued Nov. 29, 1988; 4,792,442 issued Dec. 20, 1988; 4,818,519 issued Apr. 4, 1989; 4,851,21 issued Jul. 25, 1989; 4,855,135 issued Aug. 8, 1989; 4,793,989 issued Dec. 27, 1988; 4,886,657 issued Dec. 12, 1989; 4,889,714 issued Dec. 26, 1989; 4,925,656 issued May 15, 1990; 4,975,285 issued Dec. 4, 1990; 4,978,535 issued Dec. 18, 1990; 5,200,171 issued Apr. 6, 1993; 5,348,734 issued Sep. 20, 1994; 5,618,550 issued Apr. 8, 1997, and 5,489,435 issued Feb. 6, 1996, all to Perry A. Ratcliffe, teach oral care compositions and methods of treatment using stabilized chlorine dioxide.

Compositions containing limonene among a list of components have been mentioned in the prior art. For example, US patent #5,453,276 lists limonene among anacardic acid, farnesol, citronellol, pine resin, hinokitiol, longifolene and caryophyllene that together showed antimicrobial activity.

US patents # 5,279,813, 5,273,741, 5,234,688, 5,167,951, describes antiplaque compositions containing triclosan as antibacterial agent and

polyphosphate for anti-tartar actions. In these compositions, limonene was used as stabilizer. US patent # 5,910,455 mentions limonene as an abrasive hand cleansing material in a cleanser composition. Limonene is also mentioned in US pat. 5,079,063 as antiflea agent for making flea-free carpets. Limonene is also described in US pat. 5,164,416 as skin penetrating enhancer in transdermal formulations. All of the above references are incorporated herein by reference in their entirety.

U.S. Patent 5,939,050 discloses a combination of two groups of materials that produce a synergistic antimicrobial effect. The compounds include natural and synthetic compounds such as berberine, cedarwood oil, chloramphenicol, citral, citronella oil, cocamidopropyl, dimethylglycine, and lemon oil. The lemon oil shows low antimicrobial activity but in combination with the other compounds it shows a synergistic antimicrobial effect. The lemon oil is used in a very low concentration in the final formulation of said patent. Said patent does not teach or suggest the present discovery that, inter alia, lemon oil has an unexpected activity for improving gingivitis which is not necessarily related to the antimicrobial activity which has been shown to be very low for lemon oil when lemon oil was used alone in said patent. Thus, the focus of said patent is antimicrobial activity focussing on certain components working in combination and, as indicated, said patent does not teach or suggest to a person skilled in the art that any advantage is achieved by using lemon oil or an extract thereof by itself as the primary active ingredient.

The above prior art references have not recognized that the delivery of monoterpenes with three unsaturations to the oral cavity will provide efficacy in various oral care conditions. Because prior art references have focused on the delivery of chlorine dioxide for efficacy, prior art compositions and methods of treatment may have various drawbacks.

Therefore, prior art compositions, mentioned above, have not been entirely satisfactory for the treatment and/or prevention of gingivitis, plaque, and periodontal disease. Therefore, additional efficacious compositions and methods of treatment for these purposes are desirable.

As mentioned above, the present invention relates to the delivery of monoterpenes with three unsaturations to the oral cavity for efficacy. It is the purpose of the present invention to provide compositions and methods for treating or preventing diseases of the oral cavity, such as plaque, gingivitis, and periodontal disease, by utilizing an effective amount of monoterpenes of three unsaturations wherein present in the oral care composition at the time of use.

Further, the present invention relates to oral care compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, tooth gels, tooth powders, non-abrasive gels, chewing gums, mouth sprays, and lozenges (including breath mints). These compositions comprise a minimally effective amount of Limonene.

These compositions are effective in killing, and/or altering the bacterial metabolism, and/or for a period of time suppressing the growth of, microorganisms which cause topically-treatable infections and diseases of the oral cavity, such as plaque, gingivitis, periodontal disease, and breath malodor. These compositions are also effective to affect inflammation.

Summary of Invention

According to the present invention there is now provided a composition for oral cavity treatment comprising monoterpenes with three unsaturations from natural or synthetic source as active agents in combination with a suitable carrier for prevention and treatment of oral cavity diseases.

More specifically, the present invention now provides a composition for topical, oral administration for prevention and treatment of oral disease, comprising an active agent containing at least 70% by weight monoterpenes with three unsaturations as active agent therein, in combination with a suitable carrier.

In a preferred embodiment of the present invention the composition of the active agent comprises at least 70% by weight of monoterpenes of three unsaturations with at least 60% is limonene.

In an even further preferred embodiment of the present invention monoterpenes are from natural source.

In a most preferred embodiment the monoterpenes are of essential oils of citrus.

In preferred embodiments of the present invention said essential oils is selected from the group consisting of lemon, pomella and citron comprising 70% by weight monoterpenes with three unsaturations or more.

In a most preferred embodiment of the present invention said essential oil of a citron.

In another aspect of the invention, a synergistic effect is obtained by combining limonene and monoterpenes with Carnallite or salts thereof in a synergistic and effective amount.

Thus, in another preferred embodiment of the present invention said extract is combined with a salt selected from the group consisting of $MgCl_2$, $MgBr_2$, $NaCl$, KCl , $CaCl_2$ and mixtures thereof.

In a preferred embodiment of the invention the Carnallite is present in an amount of about 5-99% wt/wt.

In a further preferred embodiment the composition has a saline concentration of about 50% and an effective amount of said extract is added immediately before application.

The composition of the present invention will be combined with a suitable carrier selected from the group consisting of toothpaste, mouthwash, lozenges, chewing gum and toothpowder.

In a preferred embodiment of the present invention monoterpenes of three unsaturations is present in an amount of up to 10% wt/wt.

In another aspect of the invention there is provided a method for oral treatment, consisting of administering to a patient a composition comprising monoterpenes of three unsaturations in combination with a suitable carrier.

In a preferred embodiment there is provided a method for oral treatment, consisting of administering to a patient a composition comprising monoterpenes of three unsaturations further comprising Carnallite in a synergistic amount, in combination with a suitable carrier.

In another aspect of the invention there is provided a method for oral treatment, consisting of administering to a patient a composition comprising an essential oil of a citron fruit in combination with a suitable carrier.

In a preferred embodiment there is provided a method for oral treatment, consisting of administering to a patient a composition comprising an essential oil of a citron fruit further comprising Carnallite in a synergistic amount, in combination with a suitable carrier.

The present invention further provides a method for treating and/or preventing plaque, dental calculus, gingivitis, periodontitis, and oral viral diseases.

In an even further preferred embodiment there is provided a method for reducing the depth of periodontal pockets in a patient, comprising administering any of the compositions mentioned above.

The extraction of the essential oil of the present invention was achieved utilizing steam distillation. In this process fresh peels were utilized resulting in about 1.5% by weight of essential oil in comparison to the original of said peels.

The monoterpene and essential oil active agents of the present invention, preferably in combination with a Carnallite salt, can also be microencapsulated by methods and with components known per se.

As stated hereinbefore, the present invention relates to compositions and methods of treating or preventing diseases of the oral cavity (e.g. plaque, gingivitis, periodontal disease), in humans or animals, by applying to the oral cavity, a safe and effective amount of monoterpenes of three unsaturations.

The term "monoterpenes of three unsaturations" as used herein, is meant to denote a composition containing at least one monoterpene of three unsaturations of the molecular formula $C_{10}H_{16}$, wherein unsaturation refers to a double bond or a cyclization. Examples are limonene containing two double bonds and one cyclic group, myrcene containing three double bonds, and sabinene, α -pinene and β -pinene.

"Safe and effective amount" as used herein is meant to denote an amount of monoterpene with three unsaturation derivatives, high enough to significantly

(positively) modify the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical/dental judgment. The safe and effective amount of monoterpenes, will vary with the particular condition.

"Toothpaste" as used herein is meant to denote paste, powder, and tooth gel formulations unless otherwise specified.

"Oral care composition" or "oral composition" as used herein is meant to denote a product which is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is retained in the oral cavity for a sufficient time to contact substantially all of the dental surfaces and/or oral mucosal tissues for purposes of oral activity.

A "pharmaceutically-acceptable excipient" or "pharmaceutically-acceptable oral carrier," as used herein, is meant to denote one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for topical, oral administration.

"Compatible," as used herein, is meant to denote that the components of the composition are capable of being commingled without interaction in a manner which would substantially reduce the composition's stability and/or efficacy for treating or preventing breath malodor, plaque, gingivitis, and periodontal disease, according to the compositions and methods of the present invention.

The carriers or excipients of the present invention can include the usual and conventional components of toothpastes (including gels and gels for subgingival application), mouth rinses, mouth sprays, chewing gums, and lozenges (including breath mints) as more fully described hereinafter. The compositions of the present invention can be dual phase compositions or single phase compositions.

The choice of a carrier to be used is basically determined by the way the composition is to be introduced into the oral cavity. If a toothpaste (including tooth gels, etc.) is to be used, then a "toothpaste carrier" is chosen as disclosed in, e.g., U.S. Pat. No. 3,988,433, to Benedict, the disclosure of which is incorporated herein by reference (e.g., abrasive materials, sudsing agents, binders, humectants, flavoring and sweetening agents, etc.). If a mouth rinse is to be used, then a "mouth

rinse carrier" is chosen, as disclosed in, e.g., U.S. Pat. No. 3,988,433 to Benedict (e.g., water, flavoring and sweetening agents, etc.). Similarly, if a mouth spray is to be used, then a "mouth spray carrier" is chosen or if a lozenge is to be used, then a "lozenge carrier" is chosen (e.g., a candy base), candy bases being disclosed in, e.g., U.S. Pat. No. 4,083,955, to Grabenstetter et al., which is incorporated herein by reference; if a chewing gum is to be used, then a "chewing gum carrier" is chosen, as disclosed in, e.g., U.S. Pat. No. 4,083,955, to Grabenstetter et al., which is incorporated herein by reference (e.g., gum base, flavoring and sweetening agents). Carriers suitable for the preparation of compositions of the present invention are well known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, etc.

Preferred compositions of the subject invention are in the form of toothpastes and tooth gels. Components of such toothpaste and tooth gels generally include one or more of a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 55%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01% to about 0.5%) and water (from about 2% to about 45%). Such toothpaste or tooth gel may also include one or more of an anticaries agent (from about 0.05% to about 0.3% as fluoride ion), and an anticalculus agent (from about 0.1% to about 13%).

Other preferred compositions of the subject invention are mouthwashes, including mouth sprays. Components of such mouthwashes and mouth sprays typically include one or more of water (from about 45% to about 95%), ethanol (from about 0% to about 25%), a humectant (from about 0% to about 50%), a surfactant (from about 0.01% to about 7%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), and a coloring agent (from about 0.001% to about 0.5%). Such mouthwashes and mouth sprays may also include one or more of an anticaries agent (from about 0.05% to about 0.3% as fluoride ion), and an anticalculus agent (from about 0.1% to about 3%).

Other preferred compositions of the subject invention are dental solutions. Components of such dental solutions generally include one or more of water (from about 90% to about 99%), preservative (from about 0.01% to about 0.5%), thickening agent (from 0% to about 5%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and surfactant (from 0% to about 5%).

The compositions of the present invention are preferably essentially free of organic solvents. The compositions of the present invention are also preferably essentially free of peroxy compounds.

Types of carriers or oral care excipients which may be included in compositions of the present invention, along with specific non-limiting examples, are:

Abrasives:

Dental abrasives useful in the topical, oral carriers of the compositions of the subject invention include many different materials. The material selected must be one which is compatible within the composition of interest and does not excessively abrade dentin. Suitable abrasives include, for example, silicas including gels and precipitates, insoluble sodium polymetaphosphate, hydrated alumina, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde.

Another class of abrasives for use in the present compositions is the particulate thermo-setting polymerized resins as described in U.S. Pat. No. 3,070,510 issued to Cooley & Grabenstetter on Dec. 25, 1962. Suitable resins include, for example, melamines, phenolics, ureas, melamine-ureas, melamine-formaldehydes, urea-formaldehyde, melamine-urea-formaldehydes, cross-linked epoxides, and cross-linked polyesters. Mixtures of abrasives may also be used.

Silica dental abrasives of various types are preferred because of their unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentine. A particularly preferred precipitated silica is the

silica disclosed in U.S. Pat. Nos. 5,603,920, issued on Feb. 18, 1997; 5,589,160, issued Dec. 31, 1996; 5,658,553, issued Aug. 19, 1997; 5,651,958, issued Jul. 29, 1997, all of which are assigned to the Procter & Gamble Co. All of these patents are incorporated herein by reference in their entirety.

Mixtures of abrasives can be used. All of the above patents regarding dental abrasives are incorporated herein by reference. The total amount of abrasive in dentifrice compositions of the subject invention preferably range from about 6% to about 70% by weight; toothpastes preferably contain from about 10% to about 50% of abrasives, by weight of the composition. Solution, mouth spray, mouthwash and non-abrasive gel compositions of the subject invention typically contain no abrasive.

Suitable surface active agents are those which are reasonably stable and form foam throughout a wide pH range. Surface active agents include nonionic, anionic, amphoteric, cationic, zwitterionic, synthetic detergents, and mixtures thereof. Many suitable nonionic and amphoteric surfactants are disclosed by U.S. Pat. Nos. 3,988,433 to Benedict; U.S. Pat. No. 4,051,234, issued Sep. 27, 1977, and many suitable nonionic surfactants are disclosed by Agricola et al., U.S. Pat. No. 3,959,458, issued May 25, 1976, both incorporated herein in their entirety by reference.

Nonionic and amphoteric surfactants

Nonionic surfactants which can be used in the compositions of the present invention can be broadly defined as compounds produced by the condensation of alkylene oxide groups (hydrophilic in nature) with an organic hydrophobic compound which may be aliphatic or alkyl-aromatic in nature. Examples of suitable nonionic surfactants include poloxamers (sold under trade name Pluronic), polyoxyethylene sorbitan esters (sold under trade name Tweens), fatty alcohol ethoxylates, polyethylene oxide condensates of alkyl phenols, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylene diamine, ethylene oxide condensates of aliphatic alcohols, long chain tertiary amine oxides, long chain tertiary phosphine oxides, long chain dialkyl sulfoxides, and mixtures of such materials.

The amphoteric surfactants useful in the present invention can be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be a straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water-solubilizing group, e.g., carboxylate, sulfonate, sulfate, phosphate, or phosphonate. Other suitable amphoteric surfactants are betaines, specifically cocamidopropyl betaine. Mixtures of amphoteric surfactants can also be employed. The present composition can typically comprise a nonionic, amphoteric, or combination of nonionic and amphoteric surfactant each at a level of from about 0.025% to about 5%.

Anionic surfactants useful herein include the water-soluble salts of alkyl sulfates having from 8 to 20 carbon atoms in the alkyl radical (e.g., sodium alkyl sulfate) and the water-soluble salts of sulfonated monoglycerides of fatty acids having from 8 to 20 carbon atoms. Sodium lauryl sulfate and sodium coconut monoglyceride sulfonates are examples of anionic surfactants of this type. Other suitable anionic surfactants are sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate. Mixtures of anionic surfactants can also be employed. The present composition typically comprises an anionic surfactant at a level of from about 0.025% to about 9%, preferably from about 0.05% to about 7%, and most preferably from about 0.1% to about 5%.

Flavoring agents can also be added to the compositions. Suitable flavoring agents include oil of wintergreen, oil of peppermint, oil of spearmint, clove bud oil, menthol, anethole, methyl salicylate, eucalyptol, cassia, 1-menthyl acetate, sage, eugenol, parsley oil, oxanone, alpha-irisone, marjoram, propenyl guaethol, cinnamon, vanillin, thymol, linalool, cinnamaldehyde glycerol acetal known as CGA, and mixtures thereof. Flavoring agents are generally used in the compositions at levels of from about 0.001% to about 5%, by weight of the composition.

Sweetening agents which can be used include sucrose, glucose, saccharin, dextrose, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, D-tryptophan, dihydrochalcones, acesulfame and

cyclamate salts, especially sodium cyclamate and sodium saccharin, and mixtures thereof. A composition preferably contains from about 0.1% to about 10% of these agents, preferably from about 0.1% to about 1%, by weight of the composition.

In addition to flavoring and sweetening agents, coolants, salivating agents, warming agents, and numbing agents can be used as optional ingredients in compositions of the present invention. These agents are present in the compositions at a level of from about 0.001% to about 10%, preferably from about 0.1% to about 1%, by weight of the composition. The coolant can be any of a wide variety of materials. Included among such materials are carboxamides, menthol, ketals, diols, and mixtures thereof.

Preferred salivating agents of the present invention include Jambus.RTM. manufactured by Takasago. Preferred warming agents include capsicum and nicotinate esters, such as benzyl nicotinate. Preferred numbing agents include benzocaine, lidocaine, clove bud oil, and ethanol.

It is preferred that the mouth rinse to be taken into the oral cavity have a concentration of monoterpenes of three unsaturations in the range of from about 0.04% to about 5.0 %, with from about 0.1% to about 2.0%, by weight of the composition, being even more preferred.

Mouth sprays preferably may have monoterpenes of three unsaturations from about 0.15% to about 10%, with from about 0.2% to about 5% more preferred.

Preferably for dentifrices (including toothpaste and tooth gels) and non-abrasive gels, the concentration of monoterpenes of three unsaturations is in the range of from about 0.4% to about 4.5%, by weight of the composition, with from about 0.75% to about 3% preferred, and from about 1.5% to about 2%, by weight of the composition, being even more preferred.

For the method of treating diseases or conditions of the oral cavity of the present invention, a safe and effective amount of monoterpenes of three unsaturations is preferably applied to the gingival/mucosal tissue and/or the teeth (for example, by rinsing with a mouthrinse, directly applying a non-abrasive gel with or without a device, applying a dentifrice or a tooth gel with a toothbrush, sucking or chewing a lozenge or breathmint, etc.) preferably for at least about 10 seconds,

preferably from about 20 seconds to about 10 minutes, more preferably from about 30 seconds to about 60 seconds. The method often involves expectoration of most of the composition following such contact. The frequency of such contact is preferably from about once per week to about four times per day, more preferably from about thrice per week to about three times per day, even more preferably from about once per day to about twice per day. The period of such treatment typically ranges from about one day to a lifetime. For particular oral care diseases or conditions the duration of treatment depends on the severity of the oral disease or condition being treated, the particular delivery form utilized and the patient's response to treatment. If delivery to the periodontal pockets is desirable, such as with the treatment of periodontal disease, a mouth rinse can be delivered to the periodontal pocket using a syringe or water injection device. These devices are known to one skilled in the art.

Active Ingredient A

Essential oils from citrus, particularly of Citron Fruit composed of at least 65% monoterpenes with three unsaturations.

Active Ingredient B

CARNALLITE having the following characteristics:

Minerals	Grams/liter
MgCl₂	170-240
NaCl	15-25
KCl	13-24
CaCl₂	40-58
MgBr₂	5-12

The Carnallite is effective in fluid absorption and in the reduction of swelling and edema. These effects are facilitated by the changes in osmotic pressure affected by the presence of the above minerals. The magnesium and the bromide have antiseptic and anti-inflammatory properties.

Silica can also be added to the above list. The silica portion of the formulation functions as a soft abrasive and polishing agent. It also has mechanical functions such as removal of dental plaque, bacteria and food particles and tends to brighten the enamel.

The potassium and calcium, in combination with fluoride (not mentioned above), induce remineralization of the bone and of the dentine which was affected by caries at the cervical area of the tooth surface. As a result, there is a decrease in the cervical sensitivity of the teeth.

The fluid absorption facilitated by salt concentration has a stimulating effect on the gingival fluid thereby creating an increased secretion/production of immunal globulins. As a result, the immunal globulin concentration within the gingivital fluid is much higher than the concentration found within the saliva. This phenomenon prevents the development of anaerobic bacteria found within the gingival pocket.

The natural materials of the present invention serve as stimulators for the immune system. They also have a local effect; they encourage the secretion of gingival fluid to gingival pockets.

Like with other homeopathic medicines, using the compositions of the present invention raises the level of immunoglobolins in the saliva, with a rise in the general saliva secretion. This prevents the pathogenic bacteria from sticking to the teeth and detains their growth and proliferation.

The above compositions encourage the creation of a new periodontal ligament replacing the ligament which has been destroyed during the Periodontitis disease by widening blood vessels, proliferating capillary blood vessels, enlarging the perfusion and remineralizing the bone and the periodontal cement.

The present invention may eliminate the use of various detergents which are a common component of toothpaste. This may resolve the problem of the unspecified inflammatory reaction that often afflicts those using regular toothpaste. One can find in the dental literature a description of the linkage between Aptsos Stomatitus and a decline in the immune reaction of the mouth and the prevalence of detergents in toothpaste.

While the invention will now be described in connection with certain preferred embodiments in the following examples so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.

Example 1: Biological effect of Limonene, pinene and myrcene oil on cells

The tests concentrated on the active agent (i.e drug) effects on anaerobic bacteria that are prevalent in oral cavity and which are known to cause damage. Two bacteria were selected: a. *Porphyromonas gingivalis* and b. *Fusobacterium nucleatum*.

Murine monocytes, J774 were used to determine possible effects on eukaryotic tissue. *Leishmania major* promastigotes served as a parasite and a non-specific eukaryotic control. Drug effects which might be related to anti- or pro- inflammatory processes were conducted. The effects on IL-10, IL-12, Interferon γ (IFN- γ) and tumor necrosis factor (TNF) were examined.

Tests were made to determine the optimal amounts of cells or bacteria needed for estimation of the drug effects. The drugs that were used comprised limonene, about 90% by weight, and about 2% of a mixture of myrcene, a and b pinenes. The examined compounds, were highly effective in all trials.

Effect on J774 murine monocytes

7500 cells were seeded in 200 μ l wells. 24 hours later the compounds were added. The drug and control (saline) were diluted 1/1 in ethanol and further diluted in ethanol. 2 μ l of the dilutions were added to the cultures. Carnallite concentration was 2.5 mg/ml. Cells and drugs were incubated for 48 hours together.

Drug effect was estimated by incorporation of tritiated thymidine which was added (0.5 μ Ci/25 μ l/each well) 18 hours before harvesting the culture in a cell harvester and measuring the radioactivity with a scintillation counter. The ED 50 of the drug is about 1/40,000. The ethanol solvent and saline control showed no effect.

Effect on Leishmania major promastigotes

150,000 promastigotes and drugs were incubated in 200 μ l medium for 48 hours. The drugs were added in 2 \square l and Thymidine was added as previously described. The culture was harvested after 48 hours.

Two citrus essential oil compositions were tested, one containing 92% limonene and the second 75% limonene.

The 92% limonene compound had an ED 50 of about 1/50,000 dilution and the 75% had an ED 50 of about 1/35,000 dilution. When Carnallite was added to the limonene compositions, an increase of about 10% of the activity was recognized.

Effect on oral bacteria.

Medium suitable for anaerobic bacterial growth was kept in anaerobic conditions for 24 hours after which bacteria and drugs were added. bacterial growth was estimated 24 hours later by spectroscopy.

Two series of experiments were conducted with *Fusobacterium nucleatum*.

a. In the first series we examined natural limonene as part of Citron essential oil (92% limonene) and mixture of Citron essential oil and Carnallite. The Limonene from Citron oil at a dilution of 1/400 inhibited about 50% of bacterial growth, the Carnallite slightly increased the activity of the oil and inhibited 60% of bacterial growth under similar concentration and conditions.

One experiment was conducted with *Porphyromonas gingivalis*.

The choice of drug dilutions was based on the results with *Fusobacterium nucleatum*. Dilution of 1/1200 killed all the bacteria.

Effects on cytokine production

200,000 mononuclear cells were incubated with Citron oil containing 92% limonene for 18 hours after which cytokines released to the supernatant were determined. All determinations were performed by Elisa using specific anticytokine monoclonal antibodies. There was no spontaneous IFN γ production in control or treated cells.

The Limonene compound which was diluted 1/300 increased IL-10, and decreased IL-12 and TNF release. This means that some anti-inflammatory processes were blocked.

Conclusions

The Limonene compositions had an effect of ED 50 when diluted 1/20000 - 1/50000, against J774 mouse monocytic cell line and promastigotes of *Leishmania major*. Concentrations of 1/400-1/1200 killed at least 50% of anaerobic bacteria.

Table 1. Summarizes the effects on *L. major* promastigotes

	1/45000	1/15000	1/5000	
Carnallite	-	-	-	
Limonene, 92%	5	56	81	
Limonene, 92% + Carnal	16	68	82	
saline	14	7	14	
Saline + Carnallite	26	22	34	

The results are percent inhibition of thymidine incorporation.

**Limonene composition was diluted in ethanol. Ethanol had no inhibitory activity.

Example 2: Formulations

Various liquid formulations were prepared using monoterpene oil as main active agent:

The following examples are made by conventional processes by mixing the following:

Example 2a--Single Phase Dentifrice

Ingredient	Wt. %
Water	65.00
Limonene oil	4.000
Sodium Fluoride	0.200
Hydrated Silica	25.00
Xanthan Gum	0.600
Sodium dodecyl sulfate (27.9% Sol'n)	4.000
Titanium Dioxide	0.500
Sodium Saccharin	0.200
Flavor	0.500
Total	100.00

Example 2b-- Mouthwash

Ingredient	Wt %
<hr/>	
Water	98.00
Limonene oil (75%)	1.25
Tween 20	0.50
Flavor	0.25
Total	100.00

Example 2c--Limonene Lozenge

Ingredient	
<hr/>	
Limonene oil	6 mg. Per lozenge
Flavor	As desired
Magnesium Stearate	7.5 mg.
Stearic Acid	75 mg.
Compressible Sugar	QS 1500 mg.

Example 2d

Non-Abrasive Gel	
Ingredient	Weight %
<hr/>	
Limonene (80%)	6.00
Tween 80	0.25

		20
Carboxymethyl cellulose	10.00	
Crystalline cellulose	1.00	
Sodium Bicarbonate	0.75	
Water	QS	100%

Disperse the Carboxymethyl cellulose in water. Thereafter, add the sodium bicarbonate and mix. Then add the Tween along with the limonene oil and mix.

Example 3:

A 6-month trial was carried out, utilizing the three following components and combinations thereof:

Component A: An extract of a citron fruit

Component B: Carnallite

Component C:

Plant extracts from:

(1) Salvia (fruticosa)

(2) Junjerus

Component A was prepared as follows: The citron leaves and the citron outer peel were boiled in water (100 °C) for up to one minute, crushed in blender and filtered. The resulting fluid was added to a salt solution having a final salt concentration of 25%.

The periodontal improvement was measured according to the Periodontal screening Index (PSI) and the results are presented in Table I:

TABLE 1

Component	A+B	B+C	C	A	B	Point of Origin
PSI	3.04	1.33	1.15	1.25	1.21	1

As can be seen, the citron extract produced better results than the Carnallite (Component B), or Component C alone, however when the citron extract (A) was

combined with the Carnallite (B) the results were about three-fold greater than any of the individual components.

Example 4:

Maximum effectiveness is accomplished in a salt solution having a concentration of 50% in an aqueous solution when adding the active ingredient A a short period before brushing. The preferred application would include the addition of one drop of ether oil onto the toothbrush shortly before brushing.

Although the effectiveness of said solution is practically instantaneous, the long-term therapeutic effect on the gums is apparent after two weeks, while the periodontal screening index (PSI), continues to increase (indicating an improvement) throughout the duration of applying the above composition.

The first observable phenomenon upon initiating treatment with the above solution is the disappearance of bleeding from the gums. In addition, during a probing procedure (the measurement of pocket depth), the bleeding effects are significantly lower. At a later stage, the teeth appear to be more rigidly anchored within the gums.

As will be seen in Table 2 below, an impressive result is the reduction in pocket depth. This result is apparent within the first week of treatment and achieves peak results after a month.

Table 2								
Pocket Reduction		Reduced Bleeding		Gingival Index		Plaque Index		Week
A+B	Control	A+B	Control	A+B	Control	A+B	Control	
84	92	6	8	1.05	0.95	1.35	2.9	1
75	92	2	9	1.1	0.75	0.8	2.85	2
62	96	0	10	1.05	0.78	0.8	2.9	4
56	92	0	10	1.15	0.8	1.0	2.8	12
100		10		1.2		3.2		Baseline

The overall results point to the following attributes:

1. The formula prevents the creation of plaque and dental calculus.
2. The formula cures gum diseases. Gingivitis as well as Periodontitis. Bleeding from the gums stops soon after initiating treatment. The depth of the periodontal pockets is reduced to half within one to two weeks of treatment.
3. The formula quickens the healing processes of inflammatory phenomenon of the oral cavity, in situations of viral diseases such as Acute Necrotizing Ulcerative Gingivitis and Recurrent Aphthosis.
4. The materials have proven to be safe and efficient.
5. In certain situations, we observed the phenomenon of remineralization of the tooth in areas of caries, especially in the cervical area of the tooth.
6. With the curing of the inflammations, the situation of those suffering from an unpleasant odor from the oral cavity (Fetor-Ex-Ore) had improved immensely.

Example 5:

Using solutions having a concentration of 10% the salts presented in table 3 below were applied after tooth brushing, in the form of a mouth wash. The mouth wash was applied for 30 seconds, twice a day, for a week. The following results were measured according to the periodontal index (PI):

TABLE 3

Salts	Carnallite	Mg Br ₂	KCl	NaCl	Point of Origin
PI	1.87	1.58	1.47	1.32	1

Example 6:

Aromatic oils of each of the fruits represented within Table 4 below were added to carnallite salt solutions having a salt concentration of 25%. The solutions were used for brushing (the teeth) for one minute, twice a day during two weeks. The following results were measured according to the periodontal index (PI):

TABLE 4

Component B in addition to	Orange	Pomella	Lemon	Citron	Point of Origin
	1.15	1.77	2.02	2.98	1

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

WHAT IS CLAIMED IS:

1. A composition for topical, oral administration for prevention and treatment of oral disease, comprising an active agent containing at least 70% by weight monoterpenes with three unsaturations as active agent therein, in combination with a suitable carrier.
2. A composition according to claim 1, wherein said active agent is a natural or synthetic mixture consisting of limonene, myrcene, α -pinene, β -pinene, sabinene and mixtures thereof, of which at least 60% by weight is limonene.
3. A composition according to claim 1, wherein said monoterpenes with three unsaturations is extracted from a citrus fruit selected from the group consisting of lemon, pomella and citron.
4. A composition according to claim 1 for topical oral administration for prevention and treatment of oral disease comprising an extract of a citrus fruit containing at least 60% Limonene in combination with a suitable carrier.
5. A composition according to claim 4, wherein said extract is an extract of the outer peel of said fruit.
6. A composition according to claim 5, wherein said extract is an aromatic oil.
7. A composition according to claim 6, wherein said extract is an ether oil.
8. A composition according to claim 4, wherein said fruit is selected from the group consisting of lemon, pomella and citron.
9. A composition according to claim 4, wherein said fruit is a citron.
10. A composition according to claim 1, further comprising a salt selected from the group consisting of $MgBr_2$, $MgCl_2$, $NaCl$, KCl , $CaCl_2$ and mixtures thereof.
11. A composition according to claim 1, further comprising Carnallite in a synergistic and effective amount.
12. A composition according to claim 11, wherein said Carnallite is present in an amount of about 5-99% wt/wt of the active composition.
13. A composition according to claim 1, wherein said suitable carrier is selected from the group consisting of toothpaste, mouthwash, lozenges, chewing gum and toothpowder.

14. A composition according to claim 1, wherein said monoterpenes are present in the carrier in an amount of up to 10% wt/wt.
15. A composition according to claim 1, wherein said monoterpenes are present in an amount of up to 2% wt/wt.
16. A method for oral treatment, consisting of administering to a patient a composition comprising a terpenoid oil consisting of at least 65% limonene oil in combination with a suitable carrier.
17. A method for treating and/or preventing plaque in a patient, comprising administering a composition of claim 5.
18. A method for treating and/or preventing dental calculus in a patient, comprising administering a composition of claim 5.
19. A method for treating and/or preventing gingivitis in a patient, comprising administering a composition of claim 5.
20. A method for treating and/or preventing periodontitis in a patient, comprising administering a composition of claim 5.
21. A method for reducing the depth of periodontal pockets in a patient, comprising administering a composition of claim 5.
22. A method according to claim 5, wherein said suitable carrier is selected from the group consisting of toothpaste, mouthwash, lozenges, chewing gum and toothpowder.
23. A mouth rinse having a concentration of monoterpenes of three unsaturations in the range of from about 0.04% to about 5.0 %, by weight of the composition.
24. A mouth rinse having a concentration of monoterpenes of three unsaturations in the range of from about 0.1% to about 2.0%, by weight of the composition.
25. Mouth sprays having a concentration of monoterpenes of three unsaturations from about 0.15% to about 10%, by weight of the composition.

26

26. Mouth sprays having a concentration of monoterpenes of three unsaturations with from about 0.2% to about 5%, by weight of the composition.
27. Toothpaste and gels having a concentration of monoterpenes of three unsaturations in the range of from about 0.4% to about 5.0%, by weight of the composition.
28. Toothpaste and gels having a concentration of monoterpenes of three unsaturations in the range of from about 0.75% to about 3% by weight of the composition.
29. Toothpaste and gels having a concentration of monoterpenes of three unsaturations in the range of from about 1.5% to about 2%, by weight of the composition.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70184 A3

(51) International Patent Classification⁷: **A61K 7/26, 7/16**

(21) International Application Number: **PCT/IL01/00276**

(22) International Filing Date: **22 March 2001 (22.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
135,220 **22 March 2000 (22.03.2000)** **IL**

(71) Applicant (for all designated States except US): **GINSOL LTD [IL/IL];** Hartum 9, Har Hotzvim, 91450 Jerusalem (IL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WOLNERMAN, Joseph, Simcha [IL/IL];** Nelson Glick Street 32, 97233 Jerusalem (IL).

(74) Agent: **WOLFF, BREGMAN AND GOLLER;** P.O. Box 1352, 91013 Jerusalem (IL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
28 February 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **A COMPOSITION CONTAINING MONOTERPENES FOR TOPICAL ORAL ADMINISTRATION**

(57) Abstract: The invention provides a composition for topical, oral administration for prevention and treatment of oral disease, comprising an active agent containing at least 70 % by weight monoterpenes with three unsaturations as active agent therein, in combination with a suitable carrier.

WO 01/70184 A3

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 135,220 PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/IL 01/ 00276	International filing date (day/month/year) 22/03/2001	(Earliest) Priority Date (day/month/year) 22/03/2000
Applicant GIN SOL LTD et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 01/00276

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K7/26 A61K7/16		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 019 602 A (DENTAL THERAPEUTICS A.B.) 26 November 1980 (1980-11-26) the whole document	1-9, 13-17, 27-29
X	US 5 945 088 A (P.A.DELLI SANTI ET AL.) 31 August 1999 (1999-08-31) column 1, line 38 - line 50; claims 1-20	1-9, 13-24
X	PATENT ABSTRACTS OF JAPAN vol. 1995, no. 09, ✓ 31 October 1995 (1995-10-31) & JP 07 165547 A (LION CORP), 27 June 1995 (1995-06-27) abstract	1,2,13, 16,20
--- -/--		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
26 November 2001	13/12/2001	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Willekens, G	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IL 01/00276

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
X	<p>DATABASE WPI / Week 199237 Derwent Publications Ltd., London, GB; AN 1992-305713 XP002184001 & KR 9 101 919 B (PACIFIC CHEM IND CO), 30 March 1991 (1991-03-30) abstract</p>	1,2,13
X	<p>FR 2 618 670 A (G.M.L. PHILIP) , 3 February 1989 (1989-02-03) the whole document</p>	1,3-9, 13,16, 19,22
A	<p>GB 2 153 679 A (COLGATE-PALMOLIVE) 29 August 1985 (1985-08-29) ✓ claims 1-4,16,19,31</p>	1-9,13, 16
A	<p>US 4 420 471 A (C.T. ELTON ET AL.) 13 December 1983 (1983-12-13) claims 1-10; examples 1-38</p>	1-9,13, 16
A	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Database accession no. 1984:557464 XP002184000 ✓ abstract & M: MINASYAN ET AL: "Obtaining a stabilized and standardized medical lye" FARMATSIYA (SOFIA), vol. 34, no. 2, 1984, pages 43-49, -----</p>	10,12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IL 01/00276

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 19602	A	26-11-1980	AU 5988280 A 20-11-1980
		BR 8008655 A 31-03-1981	
		DK 381 A 21-09-1981	
		EP 0019602 A1 26-11-1980	
		JP 56500448 T 09-04-1981	
		NO 803866 A 18-12-1980	
		SE 7903856 A 04-11-1980	
		WO 8002371 A1 13-11-1980	
US 5945088	A	31-08-1999	US 6235267 B1 22-05-2001
			US 2001009660 A1 26-07-2001
JP 07165547	A	27-06-1995	NONE
KR 9101919	B	30-03-1991	KR 9101919 B1 30-03-1991
FR 2618670	A	03-02-1989	FR 2618670 A1 03-02-1989
GB 2153679	A	29-08-1985	US 4562064 A 31-12-1985
			US 4547361 A 15-10-1985
			AT 388664 B 10-08-1989
			AT 33085 A 15-01-1989
			AU 573307 B2 02-06-1988
			AU 3856685 A 15-08-1985
			BE 901690 A1 08-08-1985
			BR 8500529 A 24-09-1985
			CA 1254149 A1 16-05-1989
			CH 668359 A5 30-12-1988
			DE 3502830 A1 14-08-1985
			DK 53585 A 10-08-1985
			ES 540246 D0 16-11-1986
			ES 8700929 A1 16-02-1987
			FR 2559387 A1 16-08-1985
			IT 1184263 B 22-10-1987
			JP 60190706 A 28-09-1985
			MX 163219 B 11-03-1992
			NL 8500359 A 02-09-1985
			PH 21607 A 11-12-1987
			PT 79930 A ,B 01-03-1985
			ZA 8500399 A 27-08-1986
			AT 390369 B 25-04-1990
			AT 131188 A 15-10-1989
US 4420471	A	13-12-1983	NONE